Head of Clinical AI Research, AI for Clinical Development

About the role

This role can be based at AstraZeneca hubs in Boston, US; Gaithersburg, US; Cambridge, UK or Barcelona, Spain. We're building a connected, end-to-end Enterprise AI engine - uniting data foundations, AI technology, process reinvention, and business-facing AI to accelerate results across the whole value chain. Success depends on being exceptional connectors: you'll actively leverage existing capabilities, celebrate and promote reuse, export breakthrough ideas across geographies and functions, and obsess over scaling impact rather than building in isolation. If you thrive in high-collaboration environments where your role is to turn complex, cross-functional problems into reusable, enterprise-wide capabilities - and where the measure of success is adoption and scale, not just innovation - you'll have the platform (and sponsorship) to make it real. About AISI AI Science & Innovation (AISI) sits at the centre of AstraZeneca's R&D AI transformation. Our remit is to build, buy and deliver the AI models and agents that change pipeline outcomes, across discovery, translational science, biomarkers and clinical development. Role Overview AstraZeneca is building a world-class AI capability for Clinical Development within the Enterprise AI Unit, with the ambition to fundamentally reimagine how AI supports the way medicines are designed, tested, and brought to patients. We are hiring a Head of Clinical AI Research to set and lead the AI research agenda for this capability and to lead a team of AI/ML researchers working at the very frontier of what AI can do for clinical development. The mission is to make trial design and delivery AI-native: to target the right treatments to exactly the right patients, to demonstrate benefit with the smallest possible number of patients and the fastest possible trial cycle times, and to raise the probability of success of every program in our pipeline. This is a rare opportunity to help revolutionize clinical development from Phase I through Phase III. In doing so, you will contribute to getting better medicines to patients faster and advance human health